0001209191-23-039508.txt : 20230623 0001209191-23-039508.hdr.sgml : 20230623 20230623182750 ACCESSION NUMBER: 0001209191-23-039508 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230621 FILED AS OF DATE: 20230623 DATE AS OF CHANGE: 20230623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rochlin Kate CENTRAL INDEX KEY: 0001898521 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39692 FILM NUMBER: 231039025 MAIL ADDRESS: STREET 1: IN8BIO, INC. STREET 2: EMPIRE STATE BUILDING, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IN8BIO, INC. CENTRAL INDEX KEY: 0001740279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825462585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Incysus Therapeutics, Inc. DATE OF NAME CHANGE: 20180510 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-21 0 0001740279 IN8BIO, INC. INAB 0001898521 Rochlin Kate C/O IN8BIO, INC. 350 5TH AVE. SUITE 5330 NEW YORK NY 10118 0 1 0 0 Chief Operating Officer 0 Employee Stock Option (right to buy) 2.01 2023-06-21 4 A 0 67800 0.00 A 2033-06-21 Common Stock 67800 67800 D Twenty-five percent (25%) of the shares subject to the option shall vest on June 21, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. /s/ Jason Minio, Attorney-in-Fact 2023-06-23